Sophonix closes RMB100m Series B round

Sophonix has recently closed a 100 million US dollars Series B round of financing led by Zero2IPO Group, with participation from Delian Capital, Anlong Investment Management, Guotai Venture Capital, existing investor ETP. Yijun Capital served as the financial advisor for this round.
This is one of the largest single financing to date in the field of POCT chemiluminescence in China.

Sophonix has recently closed a 100 million US dollars Series B round of financing led by Zero2IPO Group, with participation from Delian Capital, Anlong Investment Management, Guotai Venture Capital, existing investor ETP. Yijun Capital served as the financial advisor for this round.

This is also one of the largest single financing to date in the field of POCT chemiluminescence in China.

After completing this round of financing, Sophonix will accelerate the development and upgrade of products, promote the construction, improvement and perfection of marketing system; further strengthen the localization presence, promote the capacity building of logistics and warehousing, after-sales service and marketing.

In the meantime, the company intends to continuously expand category coverage, and further explore the expansion in niche specialty markets and overseas markets.

Founded in July 2017, Sophonix is dedicated to the development, production, sales and service of in vitro diagnostic instruments and reagents.

The company revolves around the POCT scenario, coupled with advanced testing technology platform, to provide multi-faceted precision POCT solution with better repeatability and higher accuracy.

The company currently has two product lines, pathology diagnostics and immuno-diagnostics, while the molecular diagnostics product line is being established.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/24/sophonix-closes-rmb100m-series-b-round/.

Leave a Reply

Please Login to Comment